151 related articles for article (PubMed ID: 22897944)
1. Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib.
Keyvanjah K; DePrimo SE; Harmon CS; Huang X; Kern KA; Carley W
J Transl Med; 2012 Aug; 10():165. PubMed ID: 22897944
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
Harmon CS; DePrimo SE; Raymond E; Cheng AL; Boucher E; Douillard JY; Lim HY; Kim JS; Lechuga MJ; Lanzalone S; Lin X; Faivre S
J Transl Med; 2011 Jul; 9():120. PubMed ID: 21787417
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
Deprimo SE; Huang X; Blackstein ME; Garrett CR; Harmon CS; Schöffski P; Shah MH; Verweij J; Baum CM; Demetri GD
Clin Cancer Res; 2009 Sep; 15(18):5869-77. PubMed ID: 19737953
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Burstein HJ; Elias AD; Rugo HS; Cobleigh MA; Wolff AC; Eisenberg PD; Lehman M; Adams BJ; Bello CL; DePrimo SE; Baum CM; Miller KD
J Clin Oncol; 2008 Apr; 26(11):1810-6. PubMed ID: 18347007
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
6. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
[TBL] [Abstract][Full Text] [Related]
7. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.
Zurita AJ; Khajavi M; Wu HK; Tye L; Huang X; Kulke MH; Lenz HJ; Meropol NJ; Carley W; DePrimo SE; Lin E; Wang X; Harmon CS; Heymach JV
Br J Cancer; 2015 Mar; 112(7):1199-205. PubMed ID: 25756398
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
11. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.
Mauge L; Mejean A; Fournier L; Pereira H; Etienne-Grimaldi MC; Levionnois E; Caty A; Abadie-Lacourtoisie S; Culine S; Le Moulec S; Linassier C; Théodore C; Ravaud A; Albiges L; Grine A; Tartour E; Milano G; Gille AS; Verkarre V; Helley D; Oudard S;
Clin Cancer Res; 2018 Nov; 24(22):5534-5542. PubMed ID: 30061359
[No Abstract] [Full Text] [Related]
13. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
[TBL] [Abstract][Full Text] [Related]
14. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.
Vincenzi B; Nannini M; Fumagalli E; Bronte G; Frezza AM; De Lisi D; Spalato Ceruso M; Santini D; Badalamenti G; Pantaleo MA; Russo A; Dei Tos AP; Casali P; Tonini G
Oncotarget; 2016 Oct; 7(43):69412-69419. PubMed ID: 26416414
[TBL] [Abstract][Full Text] [Related]
15. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J
BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.
Chen YY; Yeh CN; Cheng CT; Chen TW; Rau KM; Jan YY; Chen MF
World J Gastroenterol; 2011 Apr; 17(16):2113-9. PubMed ID: 21547131
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
Nowak AK; Millward MJ; Creaney J; Francis RJ; Dick IM; Hasani A; van der Schaaf A; Segal A; Musk AW; Byrne MJ
J Thorac Oncol; 2012 Sep; 7(9):1449-56. PubMed ID: 22895142
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of sunitinib malate in patients with metastatic uveal melanoma.
Mahipal A; Tijani L; Chan K; Laudadio M; Mastrangelo MJ; Sato T
Melanoma Res; 2012 Dec; 22(6):440-6. PubMed ID: 23114504
[TBL] [Abstract][Full Text] [Related]
19. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
Norden-Zfoni A; Desai J; Manola J; Beaudry P; Force J; Maki R; Folkman J; Bello C; Baum C; DePrimo SE; Shalinsky DR; Demetri GD; Heymach JV
Clin Cancer Res; 2007 May; 13(9):2643-50. PubMed ID: 17473195
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Zhu AX; Sahani DV; Duda DG; di Tomaso E; Ancukiewicz M; Catalano OA; Sindhwani V; Blaszkowsky LS; Yoon SS; Lahdenranta J; Bhargava P; Meyerhardt J; Clark JW; Kwak EL; Hezel AF; Miksad R; Abrams TA; Enzinger PC; Fuchs CS; Ryan DP; Jain RK
J Clin Oncol; 2009 Jun; 27(18):3027-35. PubMed ID: 19470923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
